Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.43 |
| ▸ | PRCP | P42785 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045705 | 1.00 | TMEM97 (0.44) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL12422790 | 0.99 | TMEM97 (0.44) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL2778680 | 0.98 | HCRTR1 (0.44) | HCRTR1HCRTR2PRCPGRIN2BAADAT | |
| SCHEMBL2778623 | 0.96 | HCRTR1 (0.43) | HCRTR1HCRTR2PRCPGRIN2BAADAT | |
| SCHEMBL934345 | 0.96 | TMEM97 (0.47) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL933934 | 0.95 | AADAT (0.46) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL2195890 | 0.93 | TMEM97 (0.45) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL2195295 | 0.93 | TMEM97 (0.46) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL934054 | 0.93 | TMEM97 (0.46) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP | |
| SCHEMBL2195007 | 0.92 | AADAT (0.44) | TMEM97SIGMAR1HCRTR1HCRTR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | TMEM97 1176/4885SIGMAR1 618/4885HCRTR1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.